ArticleMolecular cancer therapeutics2013

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Ryan T Anderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.